Application of Botulinum Neurotoxin in Male Sexual Dysfunction: Where Are We Now?

Autor:	Reddy AG; Department of Urology, Tulane University School of Medicine, New Orleans, USA., Dick BP; Department of Urology, Tulane University School of Medicine, New Orleans, USA., Natale C; Department of Urology, Tulane University School of Medicine, New Orleans, USA., Akula KP; Department of Urology, Tulane University School of Medicine, New Orleans, USA., Yousif A; Department of Urology, Tulane University School of Medicine, New Orleans, USA., Hellstrom WJG; Department of Urology, Tulane University School of Medicine, New Orleans, USA. Electronic address: whellst@tulane.edu.
Jazyk:	angličtina
Zdroj:	Sexual medicine reviews [Sex Med Rev] 2021 Apr; Vol. 9 (2), pp. 320-330. Date of Electronic Publication: 2020 Jul 05.
DOI:	10.1016/j.sxmr.2020.05.004
Abstrakt:	Introduction: Botulinum neurotoxin (BoNT) is a recognized therapeutic agent of modern medical care, routinely used to treat medical conditions affecting a variety of organ systems including the musculoskeletal, integumentary, and urological domains. Ongoing research is exploring BoNT's potential role as a therapeutic agent for a variety of male sexual pathologies. Objective: To review and analyze the literature regarding BoNT as a treatment option for male sexual dysfunction. Methods: A PubMed search was performed for English-language articles in peer-reviewed journals between 1970 and 2019 (with one article from 1897). Relevant articles referenced within these texts were also included. One article did not have an accompanied English full-text available. The following search terms were used: "Botox", "Botulinum toxin", "Botulinum toxin A", "Onabotulinum A", "Abobutlinum A", "BoNT", "BoNT-A", "Male sexual health", "Male sexual pathology", "Peyronie's disease", "Premature ejaculation", "Scrotal Pain", "Penile Retraction", "Scrotox", "Erectile Dysfunction", and "Botox in Urology". Results: There is interest in the potential role of BoNT in the treatment of male sexual pathologies. We identified studies that used BoNT to treat chronic scrotal content pain, premature ejaculation, erectile dysfunction, Peyronie's disease, penile retraction, and more. However, despite preclinical/clinical data indicating some potential efficacy and safety in these settings, a lack of robust clinical trial data has resulted in no current Food and Drug Administration-approved indications for the use of BoNT in the treatment of male sexual pathology. As a result, much of the current use of BoNT by today's providers is "off-label," and ongoing clinical trials aim to further elucidate the potential role of this therapeutic agent. Conclusion: Current data suggest that BoNT could have a potential role as a treatment option for certain types of male sexual pathologies. However, more randomized controlled trial data regarding its long-term safety and efficacy are necessary before a widespread clinical adoption can take place. Reddy AG, Dick BP, Natale C, et al. Application of Botulinum Neurotoxin in Male Sexual Dysfunction: Where Are We Now?. J Sex Med 2021;9:320-330. (Copyright © 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu